Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Lymphoma Clinical Trial

Official title:

A Phase II Study of Xisomab 3G3, a Monoclonal Antibody Preventing the Activation of FXI by FXIIa, for the Prophylaxis of Catheter-Associated Thrombosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04465760
• Other study ID #: STUDY00018976
• Secondary ID: NCI-2020-02554ST
• Status: Terminated
• Phase: Phase 2
• Start date: February 25, 2021
• Est. completion date: November 5, 2021

Study information

• Verified date: January 2024
• Source: OHSU Knight Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated blood clots (thrombosis) in patients with cancer receiving chemotherapy. Many patients with cancer develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Xisomab 3G3 is type of drug called a monoclonal antibody that may prevent blood clots caused by a catheter in patients receiving chemotherapy.

Description:

PRIMARY OBJECTIVE I. To determine the efficacy of xisomab as measured by the incidence of catheter-associated thrombosis (CAT) in individuals with a central venous catheter. SECONDARY OBJECTIVE: I. To evaluate the safety and tolerability of xisomab 3G3 in cancer patients with a PICC or indwelling catheter. EXPLORATORY OBJECTIVE: I. Assessment of drug exposure and catheter occlusions leading to medical intervention. OUTLINE: Patients receive xisomab 3G3 intravenously (IV) or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT. After completion of study, patients are followed up for 60 days.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: November 5, 2021
• Est. primary completion date: October 5, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed
• In consultation with principal investigator (PI) and treating physician, participant's cancer-directed therapy allows for a 1-day period between administration of study drug and subsequent start of planned cancer-directed therapy
• Individuals with a confirmed solid malignancy that are scheduled to undergo insertion of a PICC line or indwelling central venous catheter as part of planned anticancer therapy per institutional standards
• Must have Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Platelet count > 100 x 10^9/L
• Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Participants of childbearing potential are defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal
• Female participants of childbearing potential must agree to use adequate methods of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause
• Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy

Exclusion Criteria:

• Actively receiving treatment in another therapeutic clinical trial
• Active acute leukemia (lymphoma and myeloma are allowed)
• At time of enrollment, known contraindication to anticoagulation therapy, including:
• Clinically significant active bleeding
• Individual is within 72 hours of major surgery
• Abnormal baseline coagulation tests, including international normalized ratio (INR) > 1.5, or activated partial thromboplastin time (aPTT) prolonged
• Abnormal renal function defined by an estimated glomerular filtration rate (eGFR) < 45 mL/min
• Abnormal hepatic function defined as liver function tests (LFTs) (aspartate aminotransferase [AST], alanine aminotransferase [ALT] or total bilirubin) > 2 x the upper limit of normal or known Child-Pugh class B or C cirrhosis
• Prior history of intracranial hemorrhage
• Primary brain tumors or known brain metastasis
• Major extracranial bleed within the last 6 months where the cause has not been identified or treated
• Known bleeding diathesis
• Use of therapeutic anticoagulation or anti-platelet agents for any indication at enrollment
• At the discretion of the investigator, any other contraindication to anticoagulation therapy
• Presence of a pediatric-sized PICC line
• Participant is expected to receive chemotherapy associated with a 15% or higher incidence of grade 3-4 thrombocytopenia within 14 days of receiving study drug
• Preexisting intravenous catheter, or indwelling spinal or epidural catheter, at time of enrollment that is intended to remain for the duration of study. Participants may remain eligible if existing catheter is to be removed before placement of a catheter for cancer directed therapy. Removal of existing catheter should occur at least 24 hours prior to PICC or indwelling catheter insertion
• Previously documented hypersensitivity to either the drug or excipients
• Psychiatric illness/social situations, or any other condition, that in the opinion of the investigator, would limit compliance with study requirements
• Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 90 days after the last dose of trial treatment
• Participant is allergic to heparin or heparin derivatives
• Participants with a history of venous thromboembolism within the last 3 months

Related Conditions & MeSH terms

• Lymphoma
• Malignant Solid Neoplasm
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Myeloma
• Thrombosis

Intervention

Drug:
• Xisomab 3G3
Given IV or via catheter

Locations

Country	Name	City	State
United States	OHSU Knight Cancer Institute	Portland	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
OHSU Knight Cancer Institute	National Heart, Lung, and Blood Institute (NHLBI), Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quantification of Coagulation Measures: Platelet Count	Presented with descriptive statistics.	Up to end of treatment visit (day 18)
Other	Quantification of Coagulation Measures: Prothrombin Time/International Normalized Ratio (PT/INR)	Presented with descriptive statistics.	Up to end of treatment visit (day 18)
Other	Quantification of Coagulation Measures: Activated Partial Thromboplastin Time (aPTT)	Presented with descriptive statistics.	Up to end of treatment visit (day 18)
Other	Xisomab 3G3 Pharmacokinetics	Presented with descriptive statistics.	Up to end of treatment visit (day 18)
Other	Time to Detection of Thrombosis	Will be reported for those (expected few) subjects with symptomatic CAT.	From xisomab 3G3 infusion up to end of treatment visit (day 18)
Other	Time to Clot Symptoms	Will be reported for those (expected few) subjects with symptomatic CAT.	From xisomab 3G3 infusion up to end of treatment visit (day 18)
Other	Proportion of Patients That Had a Catheter Occlusion Requiring Medical Intervention	Results will be presented with descriptive statistics.	Up to end of treatment visit (day 18)
Primary	Incidence of Catheter-associated Thrombosis (CAT)	The incidence of overall CAT (inclusive of both symptomatic and asymptomatic events) will be assessed and reported with 95% confidence interval.	Up to end of treatment visit (day 18)
Secondary	Incidence of Major and Clinically-relevant Bleeding	Bleeding will be defined using the International Society of Thrombosis and Hemostasis definition of major bleeding for clinical investigations of anti-hemostatic medicinal products in nonsurgical patients (i.e., fatal bleeding, critical organ bleeding such as central nervous system bleeding, or bleeding causing a fall in hemoglobin of 20 g/L or more) and clinically relevant non-major bleeding (i.e., bleeding that does not fit the former definition of major bleeding but prompts medical attention). The incidence of major and clinically relevant non-major bleeding, along with 95% confidence interval, will be assessed using the safety analysis set (all patients who are exposed to the single dose of study drug).	Up to end of follow-up (60 days from time of administration)
Secondary	Incidence of Xisomab 3G3-associated Adverse Events (AEs)	Descriptive statistics of safety will be presented using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 using the safety analysis set (all patients who are exposed to the single dose of study drug). All on-study AEs, treatment-related AEs, serious adverse events (SAEs), and treatment-related SAEs will be tabulated using worst grade per National Cancer Institute (NCI) CTCAE v5.0 criteria by system organ class and preferred term. On-study lab parameters including hematology, chemistry, liver function, and renal function will be summarized using worst grade NCI CTCAE v5.0 criteria.	Up to end of follow-up (60 days from time of administration)